Haematology / Oncology B
HFA-ICOS Cardio-Oncology Risk Assessment for Anthracyclines
Heart Failure Association-International Cardio-Oncology Society risk stratification for cardiotoxicity prior to anthracycline-based chemotherapy. Classifies patients into low, moderate, high, or very high cardiac risk.
References
- Lancellotti P, et al. Cardio-oncology services: rationale, organisation, and implementation: a HFA practical guidance document. Eur J Heart Fail. 2019;21(5):537-542.
- Lyon AR, et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229-4361.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Idarubicin (Specialist drug) · Anthracycline chemotherapy
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Mavacamten · Cardiac myosin inhibitor
- Folinic Acid (Calcium Folinate / Leucovorin) · Antidote / Chemotherapy Support
- Zoledronic Acid · Bisphosphonate (IV)
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.